Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.
24 oktober 2019

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

Commissioned research update report

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case. The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta. It also offers several advantages over some of the more advanced peers such as BioArctic’s BAN2401 and Biogen’s aducanumab. We expect that future progress and generation of satisfactory data will drive the stock price and trigger an elevated company valuation.

Click here to download update report

Marketing material commissioned by AlzeCure Pharma